Filing Flows › Xeris Biopharma Holdings (XERS) › Q4 2025
Xeris Biopharma Holdings (XERS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 2, 2026
Xeris Biopharma Holdings (XERS) reported revenue of $85.8M for the fourth quarter 2025 (Q4 2025), +43% from a year earlier and +15% from the quarter before. Operating margin was 19.5%, net earnings $11.1M (12.9% of revenue).
Xeris Biopharma Holdings, Q4 2025: revenue $85.8M (+43% year over year), operating margin 19.5%, net earnings $11.1M, operating cash flow $20.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $85.8M | +15% | +43% |
| Operating profit | $16.8M | +149% | +899% |
| Net earnings | $11.1M | 18× | — |
| Operating cash flow | $20.0M | +9% | +915% |
What changed
Revenue was $85.8M in Q4 2025, up 43% year over year and up 15% from the previous quarter. Recorlev was the largest line at 53% of revenue.
Operating profit was $16.8M, a 19.5% margin (up 16.8 points year over year). Of the extra revenue versus a year earlier, 59% reached operating profit, above the 3% margin then. Total costs grew 18% against revenue growth of 43%. The fastest-growing cost line was Research & development (+29%). Net earnings were $11.1M. The effective tax rate was 0.0%.
Operating cash flow was $20.0M (up 915% year over year), 181% of net earnings. Non-cash charges added back $335K of depreciation and amortization and $5.3M of share-based compensation. Working capital and other items added $3.4M.
Questions
What was Xeris Biopharma Holdings' revenue in the fourth quarter 2025?
Xeris Biopharma Holdings (XERS) reported revenue of $85.8M for the fourth quarter 2025 (Q4 2025), +43% from a year earlier and +15% from the quarter before.
Was Xeris Biopharma Holdings profitable in the fourth quarter 2025?
Operating profit was $16.8M (19.5% of revenue) and net earnings $11.1M.